GT Biopharma, Inc. (GTBP)
| Previous close | 2.9500 |
| Open | 3.0500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.9591 - 3.1000 |
| 52-week range | 2.6100 - 10.9500 |
| Volume | |
| Avg. volume | 1,394,267 |
| Market cap | 6.556M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.0100 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 150.00 |
GlobeNewswireGT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purchase price of $4.35 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue warrants to purchase up to 740,000 shares of comm
- GlobeNewswire
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650 expected in 2H 2024Anticipate IND submission for GTB-5550 TriKE® for treatment of B7H3 positive solid tumors in Q4 2024Plan to initiate a Phase 1 dose escalation basket trial evaluating GTB-5550 in six solid tumor cancers – prostate, breast, head and neck, ovarian, lung, and GICash of approximately $9.81 million as of March 31, 2024, provides suff
- GlobeNewswire
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H 2024Anticipate submitting an IND for GTB-5550 targeting B7H3 for multiple solid tumors, including prostate and breast, in Q4 2024Cash of approximately $14 million as of December 31, 2023, provides sufficient runway to fund operations into 2025 BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT
